Daiichi Sankyo received approximately U.S. $47 million from Seagen as awarded by the arbitrator for attorneys’ fees and costs plus interest TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A dispute ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) are closing in on a pricing deal with England’s health spending watchdog to ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Daiichi Sankyo Company (TSE:4568) has seen its shares retreat recently, with a 1 ...

Daiichi Sankyo is taking another big step in its transformation to oncology drugmaker. The pharma company recently laid out plans to create an integrated oncology business unit, tapping current U.S.

Detailed price information for Daiichi Sankyo CO Ltd Ord (DSKYF) from The Globe and Mail including charting and trades.

AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for their ...

Earlier this month, Daiichi Sankyo's board met and revised its full-year consolidated forecast for the year ending March 31, 2026, while outlining a flexible hybrid manufacturing model to support ...

July 8 (Reuters) - Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for ...

Daiichi Sankyo is in trouble with the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA) yet again. But, while the firm was found to have brought discredit upon the industry, it went ...

Detailed price information for Daiichi Sankyo CO Ltd Ord (DSKYF) from The Globe and Mail including charting and trades.

TOKYO (Reuters) -Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese ...